Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kincell Bio logo — Your CDMO Partner from Clinical to Commercial

Kincell Bio

Your CDMO Partner from Clinical to Commercial

Founded 2023 United States Durham, United States 94 employees Total: $58.00M Biopharma, Biotechnology +1

General Information

Company Name Kincell Bio
Founded Year 2023
Location United States Durham, United States
Employees 94
Industries Biopharma, Biotechnology, Pharmaceutical
Business Model B2B, B2D
Revenue Model Service Fee, Project Based, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Kincell Bio. To contact Kincell Bio, visit kincellbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kincell Bio compare?

A PDF of Kincell Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kincell Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kincell Bio

Kincell Bio, founded in 2023, operates as a specialized cell therapy CDMO in the Biopharma, Biotechnology, and Pharmaceutical industries, with headquarters in the United States. Their slogan, Your CDMO Partner from Clinical to Commercial, encapsulates their mission of supporting autologous and allogeneic cell therapies from development through commercial manufacturing.

The company prides itself on being an extension of its clients' teams, emphasizing core principles: Quality First, Better Science, Reliable Supply, Personalized Service, and the Right Scale. With facilities in Gainesville, FL, and Research Triangle Park, NC, Kincell Bio offers a robust array of services including process development, assay optimization, and inspection readiness.

Recently, Kincell Bio secured a $22.00M early VC investment on May 1, 2025, from NewSpring Capital and Kineticos Life Sciences. This funding aims to de-risk development and expedite timelines, ensuring the efficient delivery of tomorrow’s cures with confidence.

Taxonomy: Cell Therapy CDMO, Autologous Cell Therapies, Allogeneic Cell Therapies, Clinical Manufacturing, Commercial Manufacturing, CMC Strategies, GMP-compliant Manufacturing, Process Development, Analytical Development, Assay Optimization, Inspection Readiness, CAR-T Therapies, CAR-M Therapies, CAR-NK Therapies, TCR-T Therapies

Services & Products

CMC Roadmap & Development
Analytical Development & Methods
Characterization & Release Testing
Early & Late Phase Process Development
Clinical & Commercial GMP Manufacturing
Tech Transfer In Playbook

Target Customers

Biotechnology Companies Cell Therapy Developers Pharmaceutical Companies Research Institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC $22.00M 2
NewSpring Capital Kineticos Life Sciences
NewSpring Capital, Kineticos Life Sciences
01 May 2025
Early VC $36.00M 1
Kineticos Life Sciences
Kineticos Life Sciences
01 Aug 2023

Kincell Bio Alternatives & Competitors

View All Alternatives
Kincell Bio vs
JOINN Biologics US Inc.
JOINN Biologics US Inc. United States

Your premier CDMO for biologics drug development and manufacturing, from early development, to IND,...

Series B
73 employees
Biopharma, Biotechnology
Kincell Bio vs
Porton Advanced | ATMP CDMO/CRO
Porton Advanced | ATMP CDMO/CRO United States

End-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical prod...

Series B
46 employees
Biotechnology, Health and Wellness
Kincell Bio vs
CoJourney
CoJourney United States

Reimagining Cell and Gene Therapy CDMO Services High Purity | High Yield | Rapid Turnaround | Reduc...

Series A
7 employees
Biopharma, Health Care
View all alternatives

FAQ About Kincell Bio

Your CDMO Partner from Clinical to Commercial
Kincell Bio was founded in 2023.
Kincell Bio is headquartered in Durham, United States.
Kincell Bio operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Cell Therapy CDMO, Autologous Cell Therapies, Allogeneic Cell Therapies and Clinical Manufacturing. Its customers include Biotechnology Companies, Cell Therapy Developers and Pharmaceutical Companies.
Kincell Bio has a B2B and B2D business model. Its revenue comes from Service Fee, Project Based and Usage Based.
Kincell Bio has approximately 94 employees.
Kincell Bio has completed 2 funding rounds, raising a total of $58.00M.
Kincell Bio offers: CMC Roadmap & Development, Analytical Development & Methods, Characterization & Release Testing, Early & Late Phase Process Development, Clinical & Commercial GMP Manufacturing, Tech Transfer In Playbook.
Top alternatives and competitors to Kincell Bio include JOINN Biologics US Inc., Porton Advanced | ATMP CDMO/CRO, CoJourney, Cellares, leon-nanodrugs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kincell Bio and JOINN Biologics US Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kincell Bio, https://bouncewatch.com/company/kincell-bio, updated 4 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes